Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
-
BUSINESS Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
-
REGULATORY LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
-
COMMENTARY Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
REGULATORY CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
-
REGULATORY Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
-
BUSINESS ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
-
REGULATORY LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
-
BUSINESS Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
-
REGULATORY PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
-
BUSINESS Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
-
BUSINESS LEO Pharma Japan Set to Follow Global Growth as Stand-Alone Sales Force Matures
December 9, 2024
-
ACADEMIA Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
-
BUSINESS First Generics of Equa Priced at 30% of Original Product
December 6, 2024
-
REGULATORY Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
-
REGULATORY DPP Submits Request to MOF for Scrapping Off-Year Revisions
December 5, 2024
-
REGULATORY (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
-
REGULATORY Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
-
REGULATORY LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…